AstraZeneca Non-Clinical PhD Studentship in Development of an Integrated Pre-Clinical Pipeline for Safety Assessment of Small Molecule and Peptide-Based Radioconjugates

Develop a preclinical safety-assessment framework for small-molecule and peptide radioconjugates. The Cambridge–AstraZeneca project combines in-vivo PET imaging with multimodal tissue analysis to study distribution and toxicity of targeted radionuclide therapies. Four years of doctoral funding support work across academic and industrial research environments.

Applicants should have or expect a first or high upper-second-class degree, or overseas equivalent, in a relevant imaging, biological, chemical, pharmaceutical, quantitative or medical subject. Overseas applicants need Home-fee eligibility or scholarship support for the international fee difference, which cannot be self-funded.